PlainPharmaWatch

CMS Open Payments · Program Year 2024

Archimmune Therapeutics Inc.

Archimmune Therapeutics Inc. reported $142,036.52 across General Payments, Research, and Ownership to 1 physicians and teaching hospitals across 2 transactions.

See the rankings → How this is sourced
$142.0K
All-tracks total
2
Transactions
1
Recipients
−$40.3K
General Payments vs PY2023

Archimmune Therapeutics Inc. reported $142,036.52 across all CMS Open Payments tracks (General + Research + Ownership) to 1 physicians and teaching hospitals in Program Year 2024 - ranking #1091 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $897.86, averaging $142.0K per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer archimmune-therapeutics-inc Archimmune Therapeutics Inc.

$142.0K · #1091/1,925 · 0.0% industry · PY2024

  • TOT $142.0K
  • RANK #1091
  • SHARE 0.0%
  • TXN 2
  • RCP 1
  • CAT 1
  • GEN $897.86
  • ΔGEN −$40.3K
  • TOP1 100.0%
  • PY 2024

Volume peers

Nearest volume peer: Beyond Air, Inc. ($141.7K)

Accuray Incorporated$143.0KNordic Pharma, Inc.$142.6KArchimmune Therapeutics Inc.…$142.0KBeyond Air, Inc.$141.7KCeltic Biodevices LLC$141.4K
All-tracks payment totals near Archimmune Therapeutics Inc. (CMS Open Payments PY2024)

Archimmune Therapeutics Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Archimmune Therapeutics Inc.'s CMS-reported General Payments decreased by $40.3K (−97.8%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2023: ARCHIMMUNE THERAPEUTICS INC.PY2024: Archimmune Therapeutics Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$41.2KPY2024$897.86
PY2023
$41,245.48
PY2024
$897.86

What the Data Shows for Archimmune Therapeutics Inc.

Averaging $71.0K per transaction and $142.0K per recipient, Archimmune Therapeutics Inc.'s Program Year 2024 total comes to $142,036.52 across 2 transactions and 1 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #1091 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

"Travel and Lodging" leads the 1-category general-payment breakdown below at $897.86 (100.0% of General Payments, 1 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

Across 1 types of general payments, Archimmune Therapeutics Inc.'s largest category was "Travel and Lodging" at $897.86 - 100.0% of General Payments.

How Archimmune Therapeutics Inc. divides its payments

Ranked by total dollars reported per category

1. Travel and Lodging$897.86
Payment Type Amount Transactions
Travel and Lodging $897.86 1

Recipient Concentration in General Payments

The five largest recipient relationships account for $897.86 (100.0%) of $897.86 in this company's General Payments records across 1 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Archimmune Therapeutics Inc.

The five named recipients with the highest reported General Payments from this company

Andrew Zhuang Wang$897.86
  1. 1

    Andrew Zhuang Wang

    $897.86 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Archimmune Therapeutics Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Archimmune Therapeutics Inc..

Clarix Imaging Corporation

HHI 10000

Sentrimed, Inc.

HHI 10000

Nurami Medical Inc

HHI 10000

Fluoptics Sas

HHI 10000

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Archimmune Therapeutics Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Archimmune Therapeutics Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.